1.71  0.142 (9.06%)		03-09 16:00
Open: 1.61 High: 1.855 Volume: 1,763,224		Pre. Close: 1.568 Low: 1.595 Market Cap: 60(M)

Short term
Mid term
Targets	6-month :	2.16	1-year :	2.53
Resists	First :	1.85	Second :	2.16
Pivot price	1.37
Supports	First :	1.41	Second :	1.14
MAs	MA(5) :	1.53	MA(20) :	1.34
	MA(100) :	1.6	MA(250) :	1.73
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	90.4	D(3) :	90
RSI	RSI(14): 72.6
52-week	High :	2.56	Low :	1.12

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ OSTX ] has closed above the upper band by 6.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 83.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	1.62 - 1.62	1.62 - 1.63
Low:	1.47 - 1.47	1.47 - 1.48
Close:	1.56 - 1.57	1.57 - 1.58

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Mon, 09 Mar 2026
D. Boral Capital Reaffirms Buy Rating for OS Therapies (NYSEAMERICAN:OSTX) - MarketBeat

Mon, 09 Mar 2026
FDA meeting shift puts OS Therapies cancer shot on $205M voucher path - Stock Titan

Fri, 06 Mar 2026
OS Therapies Raises $2 Million via Convertible Notes - TipRanks

Tue, 03 Mar 2026
OS Therapies Incorporated announced that it has received $2 million in funding - marketscreener.com

Sun, 01 Mar 2026
OS Therapies Incorporated (NYSEAMERICAN:OSTX) Short Interest Update - MarketBeat

Sun, 01 Mar 2026
OSTX - OS THERAPIES INCORPORATED Latest Stock News & Market Updates - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.